Short Courses and Special Courses
SC41 - From Base to Apex: The Past, Present, and Future of Prostate Pathology
Thursday, March 22, 2018 - 1:00 pm - 4:30 pm
This Short Course session includes up to a half-hour break.
3 CME and 3 SAMs
Brian D. Robinson, MD, Weill Cornell Medical College, New York, NY
Scott A. Tomlins, MD, PhD, University of Michigan, Ann Arbor, MI
Mark A. Rubin, MD, Weill Cornell Medical College, New York, NY
Prostate cancer remains the most common non-cutaneous cancer in men with over 180,000 new cases diagnosed each year. Many tumors are indolent and do not require definitive therapy (e.g. surgery, radiation), but can be monitored over time (i.e. active surveillance). As pathologists, we play a key role in determining the ultimate course of patient care.
The role of pathologists in the diagnosis and management of patients with prostate cancer has become increasingly complex. Not only do they diagnose and classify prostate cancer in needle core biopsy samples, but they must be aware of clinically relevant factors to effectively communicate findings to clinicians. Molecular assays are increasingly applied to needle core samples to guide treatment decisions and provide prognostic information, so pathologists must understand how to interpret test results and the potential limitations of various assays. Finally, the field of urologic pathology is continually evolving, particularly with respect to applications of molecular testing. Pathologists need to stay abreast of these changes in order to maintain an integral role in the care of prostate cancer patients.
Upon completion of this educational activity, the learner will be able to:
- Accurately diagnose prostate cancer with judicious use of ancillary stains and reduce the number of “atypical” diagnoses
- Recommend appropriate diagnostic and prognostic tests to clinicians and patients
- Provide adequate, detailed prostate biopsy reports using current prostate cancer grading scales
Continuing Medical Education and Maintenance of Certification
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Maintenance of Certification (MOC). Physicians must take and pass the post-test in order to claim SAMs credit.
Physicians can earn a maximum of 3 SAM credit hours.
Return to 2018 Annual Meeting Short Course Page